NEW YORK (GenomeWeb News) – SuperGen has gained access to technologies from Molecular Response under a deal announced today.
Pharmaceutical firm SuperGen will have limited access to Molecular Response's "living" cell bank of primary tumor cells, high-content imaging, and molecular characterization platforms.
Financial and other terms of the agreement were not released.
Based in Dublin, Calif., SuperGen discovers and develops cancer therapeutics in epigenetic and cell signaling modulation. San Diego-based Molecular Response develops companion diagnostics and other tools for targeted therapeutic development.
"We believe our high-resolution, high-content cell-based platforms and exclusive patient-derived primary tumor cell bank provide the best model for predicting efficacy of novel drugs," Molecular Response CEO Cyrus Mirsaidi, said in a statement. "I expect our collaboration with Supergen to set a leading example in translational medicine."